<?xml version="1.0" encoding="UTF-8"?>
<!--
  Copyright SemanticBits, Northwestern University and Akaza Research
  
  Distributed under the OSI-approved BSD 3-Clause License.
  See http://ncip.github.com/caaers/LICENSE.txt for details.
-->
<payload>
    <system>adeers</system>
    <response>
        <entity>study</entity>
        <operation name="getStudyDetails">
            <data>
                <StudyDetails xmlns="">
                    <ctcVersion>4.0</ctcVersion>
                    <currentStatus>Active</currentStatus>
                    <currentStatusDate>2007-07-02</currentStatusDate>
                    <localDocumentNumber>Z1041</localDocumentNumber>
                    <monitoringMethod>CDUS - Abbreviated</monitoringMethod>
                    <nciDocumentNum>ACOSOG-Z1041</nciDocumentNum>
                    <participationType>Group</participationType>
                    <phase>III</phase>
                    <primaryStudyType>Treatment</primaryStudyType>
                    <sponsorOrganization>CTEP</sponsorOrganization>
                    <studyAgents>
                        <studyAgent createdDate="09-29-2005 08:22:12" lead="No" updatedDate="07-09-2007 11:32:10">
                            <agent>
                                <nscNumber>26271</nscNumber>
                                <agentName>Cyclophosphamide</agentName>
                                <agentStatus>Active</agentStatus>
                                <inds>
                                </inds>
                            </agent>
                            <commercialInvestigational>Commercial</commercialInvestigational>
                        </studyAgent>
                        <studyAgent createdDate="09-29-2005 08:22:12" lead="No" updatedDate="07-09-2007 11:32:19">
                            <agent>
                                <nscNumber>256942</nscNumber>
                                <agentName>Epirubicin (Ellence)</agentName>
                                <agentStatus>Active</agentStatus>
                                <inds>
                                    <ind lead="No">
                                        <indHolder>CTEP</indHolder>
                                        <indNumber>6667</indNumber>
                                    </ind>
                                </inds>
                            </agent>
                            <commercialInvestigational>Commercial</commercialInvestigational>
                        </studyAgent>
                        <studyAgent createdDate="09-29-2005 08:22:12" lead="No" updatedDate="07-09-2007 11:32:01">
                            <agent>
                                <nscNumber>19893</nscNumber>
                                <agentName>5-Fluorouracil (5-FU)</agentName>
                                <agentStatus>Active</agentStatus>
                                <inds>
                                    <ind lead="Yes">
                                        <indHolder>CTEP</indHolder>
                                        <indNumber>7777777</indNumber>
                                        <indEndDate></indEndDate>
                                    </ind>
                                </inds>
                            </agent>
                            <commercialInvestigational>Commercial</commercialInvestigational>
                        </studyAgent>
                        <studyAgent createdDate="09-29-2005 08:22:13" lead="No" updatedDate="07-09-2007 11:32:31">
                            <agent>
                                <nscNumber>673089</nscNumber>
                                <agentName>Paclitaxel (Taxol)</agentName>
                                <agentStatus>Active</agentStatus>
                                <inds>
                                    <ind lead="Yes">
                                        <indHolder>CTEP</indHolder>
                                        <indNumber>8888888</indNumber>
                                        <indEndDate> </indEndDate>
                                    </ind>
                                </inds>
                            </agent>
                            <commercialInvestigational>Commercial</commercialInvestigational>
                        </studyAgent>
                        <studyAgent createdDate="09-29-2005 08:22:13" lead="Yes" updatedDate="05-12-2010 12:18:53">
                            <agent>
                                <nscNumber>688097</nscNumber>
                                <agentName>Trastuzumab (Herceptin)</agentName>
                                <agentStatus>Active</agentStatus>
                                <inds>
                                    <ind lead="Yes">
                                        <indHolder>CTEP</indHolder>
                                        <indNumber>9999999</indNumber>
                                        <indEndDate>09-29-2005 08:22:13</indEndDate>
                                    </ind>
                                </inds>
                            </agent>
                            <commercialInvestigational>Investigational</commercialInvestigational>
                        </studyAgent>
                    </studyAgents>
                    <studyDevices/>
                    <studyDiseases>
                        <studyDisease createdDate="09-29-2005 08:24:51" lead="Yes" updatedDate="">
                            <diseaseName>Invasive breast carcinoma</diseaseName>
                            <reportingMedDRA>10006190</reportingMedDRA>
                        </studyDisease>
                    </studyDiseases>
                    <studyOrganizations>
                        <studyOrganization createdDate="09-29-2005 08:18:22" role="Document to Lead Organization"
                                           updatedDate="05-26-2006 15:49:08">
                            <localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/>
                            <organization>
                                <ctepId>ACOSOG</ctepId>
                                <organizationName>American College of Surgeons Oncology Trials Group</organizationName>
                                <organizationType>CGP</organizationType>
                            </organization>
                            <status>Active</status>
                            <principalInvestigator ctepInvestigatorId="10610">
                                <firstname>Aman</firstname>
                                <middlename>U.</middlename>
                                <lastname>Buzdar</lastname>
                                <email>abuzdar@mdanderson.org.x</email>
                                <principalInvestigatorStatus>Active</principalInvestigatorStatus>
                            </principalInvestigator>
                        </studyOrganization>
                        <studyOrganization createdDate="09-28-2005 15:58:09" role="Document to Participant Organization"
                                           updatedDate="04-04-2007 12:55:09">
                            <localDocumentNumber>NSABP-B-41</localDocumentNumber>
                            <organization>
                                <ctepId>NSABP</ctepId>
                                <organizationName>National Surgical Adjuvant Breast and Bowel Project</organizationName>
                                <organizationType>CGP</organizationType>
                            </organization>
                            <status>Inactive</status>
                        </studyOrganization>
                        <studyOrganization createdDate="03-03-2008 10:47:36" role="Document to Participant Organization"
                                           updatedDate="">
                            <localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/>
                            <organization>
                                <ctepId>CTSU</ctepId>
                                <organizationName>Cancer Trials Support Unit</organizationName>
                                <organizationType>CGP</organizationType>
                            </organization>
                            <status>Active</status>
                        </studyOrganization>
                    </studyOrganizations>
                    <studyTherapies>
                        <therapy createdDate="09-29-2005 08:25:11" updatedDate="07-11-2007 16:17:14">
                            <ctepName>Drug and/or Immunotherapy</ctepName>
                            <medDRACode>90003006</medDRACode>
                            <preferredTerm xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/>
                        </therapy>
                        <therapy createdDate="09-29-2005 08:25:11" updatedDate="07-11-2007 16:12:21">
                            <ctepName>Surgery</ctepName>
                            <medDRACode>10042609</medDRACode>
                            <preferredTerm>Surgery</preferredTerm>
                        </therapy>
                    </studyTherapies>
                    <studyTreatmentAssignments>
                        <studyTreatmentAssignment createdDate="09-29-2005 09:56:30" updatedDate="10-01-2009 16:08:51">
                            <tacDbId>14250</tacDbId>
                            <code>ARM 1</code>
                            <description>Chemotherapy Regimen - (FEC)
                                Cycle = 21 days: (Max = 4 cycles)
                                5-FU: 500mg/m2 IVP on day 1
                                Epirubicin: 75mg/m2 IV over 15 min on day 1
                                Cyclophosphamide: 500mg/m2 IV over 30 min on day 1

                                21 days after last dose of FEC:
                                Cycle = 12 weeks:
                                Paclitaxel: 80mg/m2 IV over 60 min weekly
                                Trastuzumab: 4mg/kg IV over 90 min week 1, then 2mg/kg IV over 30 min for remaining 11
                                weeks

                                3-4 wks after last preop dose of Trastuzumab, begin
                                Cycle = 3 weeks:
                                Trastuzumab: 6mg/kg IV over 60 min
                                (Continue until 52 wks from first preop dose reached)
                            </description>
                        </studyTreatmentAssignment>
                        <studyTreatmentAssignment createdDate="09-29-2005 10:03:08" updatedDate="10-01-2009 16:08:41">
                            <tacDbId>14251</tacDbId>
                            <code>ARM 2</code>
                            <description>Chemotherapy Regimen - (FEC)
                                Cycle = 12 weeks:
                                Paclitaxel: 80mg/m2 IV over 60 min weekly
                                Trastuzumab: 4mg/kg IV over 90 min week 1, then 2mg/kg IV over 30 min during subsequent
                                12 weeks

                                14 days after last dose Paclitaxel, begin FEC + Trastuzumab -
                                Cycle = 21 days: (Max = 4 cycles)
                                5-FU: 500mg/m2 IVP on day 1
                                Epirubicin: 75mg/m2 IV over 15 min on day 1
                                Cyclophosphamide: 500mg/m2 IV over 30 min on day 1
                                Trastuzumab: 2mg/kg IV over 30 min weekly x 12 weeks.

                                3-4 weeks after last preop dose of Trastuzumab, begin
                                Cycle = 3 weeks:
                                Trastuzumab: 6mg/kg IV over 60 min
                                (Continue until 52 wks from first preop dose)
                            </description>
                        </studyTreatmentAssignment>
                    </studyTreatmentAssignments>
                    <title>A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel
                        Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75
                        Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer
                    </title>
                </StudyDetails>
            </data>
        </operation>
    </response>
</payload>
